News | January 23, 2026
Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Over 8.8?million Indians aged 60 and above currently live with dementia,
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Subscribe To Our Newsletter & Stay Updated
